Gossamer bio to provide updated seralutinib torrey open-label extension data at the american thoracic society 2024 international conference

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), will present updated seralutinib torrey open-label extension data at the american thoracic society 2024 international conference, which takes place may 17-22 in san diego, california. details.
GOSS Ratings Summary
GOSS Quant Ranking